TransThera Sciences (Nanjing), Inc. filed its Monthly Return for the period ended 30 April 2026, highlighting a placement-driven expansion of its equity base.

The company allotted 5.09 million new H shares on 21 April 2026 at HKD 57.03 per share, an issuance previously approved on 4 August 2025. The transaction lifted the number of issued H shares to 308.85 million, up from 303.77 million a month earlier. Unlisted ordinary shares remained unchanged at 95.23 million.

Following the placement, authorised and issued share capital stood at 404.08 million shares with a par value of RMB 1 each. No treasury shares were outstanding, and no share options, warrants or convertible instruments were exercised during the month.

The issuer confirmed compliance with the Main Board’s minimum public-float requirement of 25 percent for its H shares. All regulatory filings and corporate formalities associated with the share issuance were completed, according to statements signed by the Joint Company Secretary.